Long-term potentiation (LTP) in the central amygdala (CeA) is enhanced after prolonged withdrawal from chronic cocaine and requires CRF1 receptors. 2007

Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
Department of Pharmacology and Toxicology, Medical Branch, University of Texas, 301 University Blvd., Galveston, TX 77555-1031, USA.

The amygdala is part of the brain reward circuitry that plays a role in cocaine-seeking and abstinence in animals and cocaine craving and relapse in humans. Cocaine-seeking is elicited by cocaine-associated cues, and the basolateral amygdala (BLA) and CeA are essential in forming and communicating drug-related associations that are thought to be critical in long-lasting relapse risk associated with drug addiction. Here we simulated a cue stimulus with high-frequency stimulation (HFS) of the BLA-CeA pathway to examine mechanisms that may contribute to drug-related associations. We found enhanced long-term potentiation (LTP) after 14-day but not 1-day withdrawal from 7-day cocaine treatment mediated through N-methyl-d-aspartate (NMDA) receptors (NRs), L-type voltage-gated calcium channels (L-VGCCs), and corticotropin-releasing factor (CRF)(1) receptors; this was accompanied by increased phosphorylated NR1 and CRF(1) protein not associated with changes in NMDA/AMPA ratios in amygdalae from cocaine-treated animals. We suggest that these signaling mechanisms may provide therapeutic targets for the treatment of cocaine cravings.

UI MeSH Term Description Entries
D008297 Male Males
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003042 Cocaine An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine HCl,Cocaine Hydrochloride,HCl, Cocaine,Hydrochloride, Cocaine
D003463 Cues Signals for an action; that specific portion of a perceptual field or pattern of stimuli to which a subject has learned to respond. Cue
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical
D000679 Amygdala Almond-shaped group of basal nuclei anterior to the INFERIOR HORN OF THE LATERAL VENTRICLE of the TEMPORAL LOBE. The amygdala is part of the limbic system. Amygdaloid Body,Amygdaloid Nuclear Complex,Amygdaloid Nucleus,Archistriatum,Corpus Amygdaloideum,Intercalated Amygdaloid Nuclei,Massa Intercalata,Nucleus Amygdalae,Amygdalae, Nucleus,Amygdaloid Bodies,Amygdaloid Nuclear Complices,Amygdaloid Nuclei, Intercalated,Amygdaloid Nucleus, Intercalated,Amygdaloideum, Corpus,Amygdaloideums, Corpus,Archistriatums,Complex, Amygdaloid Nuclear,Complices, Amygdaloid Nuclear,Corpus Amygdaloideums,Intercalata, Massa,Intercalatas, Massa,Intercalated Amygdaloid Nucleus,Massa Intercalatas,Nuclear Complex, Amygdaloid,Nuclear Complices, Amygdaloid,Nuclei, Intercalated Amygdaloid,Nucleus, Amygdaloid,Nucleus, Intercalated Amygdaloid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance

Related Publications

Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
July 2005, Journal of neurochemistry,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
January 2006, The European journal of neuroscience,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
September 2006, The European journal of neuroscience,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
January 1990, Pharmacological research,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
January 1990, NIDA research monograph,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
June 2007, Molecular pain,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
July 2011, The European journal of neuroscience,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
March 2004, Science (New York, N.Y.),
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
August 2010, The journal of pain,
Yu Fu, and Sebastian Pollandt, and Jie Liu, and Balaji Krishnan, and Kathy Genzer, and Luis Orozco-Cabal, and Joel P Gallagher, and Patricia Shinnick-Gallagher
March 2012, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!